Trial reportDiabetes2012
Platelet isoprostane overproduction in diabetic patients treated with aspirin.
Trial report in Diabetes, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial.Journal of diabetes · 2025Trial
- Diabetes mellitus in patients with heart failure and reduced ejection fraction: a post hoc analysis from the WARCEF trial.Internal and emergency medicine · 2024Trial
- Interplay between Nox2 Activity and Platelet Activation in Patients with Sepsis and Septic Shock: A Prospective Study.Oxidative medicine and cellular longevity · 2020Trial
- Trial
- Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation.Acta diabetologica · 2015Trial
- Significance of 8-iso-PGFAmerican heart journal plus : cardiology research and practice · 2026Review
- Insulin Resistance and Platelet Hyperactivity: Hematological Insights and Nutritional Strategies for Vascular Protection.Nutrients · 2026Review
- Review
- Insulin Resistance-Induced Platelet Hyperactivity and a Potential Biomarker Role of Platelet Parameters: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study.Antioxidants (Basel, Switzerland) · 2022Article
- The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors.Antioxidants (Basel, Switzerland) · 2021Review
- Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus.Frontiers in pharmacology · 2021Article
- Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease.Frontiers in pharmacology · 2021Review
- Influence of Cardiometabolic Risk Factors on Platelet Function.International journal of molecular sciences · 2020Review
- Effect of corticosteroids on myocardial injury among patients hospitalized for community-acquired pneumonia: rationale and study design. The colosseum trial.Internal and emergency medicine · 2020Article
- Early decrease of oxidative stress by non-invasive ventilation in patients with acute respiratory failure.Internal and emergency medicine · 2018Article
- Role of aspirin in patients with septic shock: a complex and intriguing relationship.Intensive care medicine · 2016Article
- STAT3 methylation in white blood cells as a novel sensitive biomarker for the toxic effect of low-dose benzene exposure.Toxicology research · 2016Article
- Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats.Naunyn-Schmiedeberg's archives of pharmacology · 2014Article
- Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro.Transfusion · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspirin modestly influences cardiovascular events in patients with type 2 diabetes mellitus (T2DM), but the reason is unclear. The aim of the study was to determine whether in T2DM patients aspirin enhances platelet isoprostanes, which are eicosanoids with proaggregating properties derived from arachidonic acid oxidation by platelet NOX2, the catalytic subunit of reduced NAD phosphate oxidase. A cross-sectional study was performed comparing T2DM patients, treated (n = 50) or not treated (n = 50) with 100 mg/day aspirin, with 100 nondiabetic patients, matched for age, sex, atherosclerosis risk factors, and aspirin treatment. A short-term (7 days) treatment with 100 mg/day aspirin also was performed in 36 aspirin-free diabetic and nondiabetic patients. Higher platelet recruitment, platelet isoprostane, and NOX2 activation was found in diabetic versus nondiabetic patients and in aspirin-treated diabetic patients versus nontreated patients (P < 0.001). Platelet thromboxane (Tx) A(2) (P < 0.001) was inhibited in all aspirin-treated patients. In the interventional study, aspirin similarly inhibited platelet TxA(2) in diabetic and nondiabetic patients (P < 0.001). Platelet recruitment, isoprostane levels, and NOX2 activation showed a parallel increase in diabetic patients (P < 0.001) and no changes in nondiabetic patients. These findings suggest that in aspirin-treated diabetic patients, oxidative stress-mediated platelet isoprostane overproduction is associated with enhanced platelet recruitment, an effect that mitigates aspirin-mediated TxA(2) inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.